NCT06765252 Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
| NCT ID | NCT06765252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ain Shams University |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2025-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-04-01 with a primary completion date of 2025-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Eligibility Criteria
Inclusion Criteria: * Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy * Age \> 18 years * ECOG PS 0-2. Exclusion Criteria: * Patients treated with irinotecan * Lack of physical integrity of the upper gastrointestinal tract * Patients with malabsorption syndrome * Patients having inability to take oral medication * Patients with poor performance status * Patients with chronic diarrhea as ulcerative colitis or Crohn's disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06765252 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06765252 currently recruiting?
Yes, NCT06765252 is actively recruiting participants. Contact the research team at raghad.essam22@pharma.asu.edu.eg for enrollment information.
Where is the NCT06765252 trial being conducted?
This trial is being conducted at Shibīn al Kawm, Egypt.
Who is sponsoring the NCT06765252 clinical trial?
NCT06765252 is sponsored by Ain Shams University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.